Hong Kong – Alphamab Oncology executed an on-market share buyback on 3 November 2026, purchasing 160,000 ordinary shares at prices ranging from HKD 6.055 to HKD 6.18. The transaction cost HKD 0.98 million, equating to a volume-weighted average of HKD 6.11 per share.

The repurchased shares, equal to 0.0166% of the company’s outstanding share capital, were retained as treasury shares. As a result, Alphamab Oncology’s treasury stock rose to 8.62 million shares, while issued shares outstanding declined marginally to 965.76 million. Total issued shares, including treasury shares, remained unchanged at 974.38 million.

The buyback forms part of the mandate approved on 12 June 2026, which authorises the repurchase of up to 96.85 million shares. Cumulative repurchases under this mandate now total 2.75 million shares, representing 0.28% of the company’s issued share count at the mandate date.

In line with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on new share issues or the disposal of treasury shares until 3 December 2026.